Strata Critical Medical, Inc. — Form SCHEDULE 13D
Filed October 15, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 68/100
What the filing says
Third Point LLC and Daniel S. Loeb filed a joint Schedule 13D on October 15, 2026, disclosing share transactions in Strata Critical Medical. Between August 31 and October 13, 2026, Third Point Master Fund LP and Third Point Ultra Master Fund L.P. engaged in coordinated trading: selling 43,500 shares combined in August–September at $5.11–$5.66, then aggressively buying 126,511 shares in October 12–13 at $4.53–$4.55 as price declined. Net position increased materially; filing triggered by reaching 5% beneficial ownership threshold.
Why this rating
Major activist stake (~5%+ threshold) in $264M company warrants 13D; price decline during buying suggests pressure or opportunism. Material but not control-level yet.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.